Bortezomib Treatment Modulates Autophagy in Multiple Myeloma

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma

Although the introduction of bortezomib as a therapeutic strategy has improved the overall survival of multiple myeloma (MM) patients, 15−20% of high-risk patients do not respond to bortezomib over time or become resistant to treatment. Therefore, the development of new therapeutic strateg...

Full description

Bibliographic Details
Main Authors: Giuseppe Di Lernia, Patrizia Leone, Antonio Giovanni Solimando, Alessio Buonavoglia, Ilaria Saltarella, Roberto Ria, Paolo Ditonno, Nicola Silvestris, Lucilla Crudele, Angelo Vacca, Vito Racanelli
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Journal of Clinical Medicine
Subjects:
autophagy
angiogenesis
multiple myeloma
plasma cells
endothelial cells
drug resistance
bortezomib
Online Access:https://www.mdpi.com/2077-0383/9/2/552

Internet

https://www.mdpi.com/2077-0383/9/2/552

Similar Items